Dharti Proteins Limited authorized a borrowing limit of ₹5,000 crore during its board meeting on September 1, 2026. The company also approved alterations to its Memorandum of Association (MOA) and Articles of Association (AOA), seeking shareholder approval at the upcoming annual general meeting.

The Board noted the resignation of M/s. PSG & Associates as internal auditor due to personal commitments, effective August 31, 2026. It appointed M/s. Mikil Vora & Associates as the new internal auditor for a five-year term covering FY27 to FY31.

Corporate Governance Updates

The appointment of Mikil Vora & Associates follows a recommendation from the Audit Committee. The firm will conduct internal audits for financial years 2026-27 through 2030-31, subject to applicable provisions of the Companies Act, 2013.

Strategic Capitalization

The Board authorized increasing borrowing limits under Section 180(1)(c) of the Companies Act, 2013. The total amount borrowed shall not exceed ₹5,000 crore at any time. These funds are intended for working capital requirements and capital expenditure.

Additionally, the Board authorized investments, loans, guarantees, or securities up to ₹5,000 crore under Section 186 of the Companies Act, 2013. Both authorizations are subject to necessary approvals.

Regulatory Filings

The company proposed altering the Object Clause in its MOA to expand its operational scope. This includes manufacturing edible oils, processing agricultural produce, and dealing in food products. The new MOA and AOA were adopted to align with current corporate governance requirements.

Dharti Proteins convened its 32nd Annual General Meeting for September 28, 2026, to seek shareholder approval for these changes. Mr. Kamlesh Mahendrabhai Shah was appointed as the scrutinizer for the e-voting process.

Dharti Proteins reported a net loss of ₹14.28 lakh for the quarter ended June 30, 2026, widening from a loss of ₹4.60 lakh in the corresponding period of the previous year. The company recorded nil revenue from operations during Q1FY27, while total expenses increased to ₹14.34 lakh from ₹6.89 lakh in the prior year quarter. The unaudited standalone financial results were approved by the Board of Directors at a meeting held on July 15, 2026.

The company’s other income declined significantly to ₹0.06 lakh in Q1FY27 from ₹2.29 lakh in the quarter ended June 30, 2025. Employee benefits expense stood at ₹2.64 lakh, while other expenses accounted for ₹11.70 lakh during the reported quarter. There were no exceptional or extraordinary items recorded in Q1FY27, unlike the preceding quarter ended March 31, 2026, which saw exceptional items of ₹39.17 lakh.

Financial Performance

The table below summarizes the key financial metrics for Dharti Proteins for the quarter ended June 30, 2026, compared with the previous year.

Auditor and Regulatory Compliance

The statutory auditors, M/s. N. S. Nanavati & Co., Chartered Accountants, performed a limited review of the financial results in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The auditors issued an unmodified opinion on the unaudited standalone financial results. The Audit Committee reviewed the results prior to Board approval.

Earnings per share (EPS) for the quarter ended June 30, 2026, was reported at (₹2.86) on both a basic and diluted basis. The paid-up equity share capital remained at ₹50.00 lakh with a face value of ₹10 per share. The financial results were prepared in compliance with the Indian Accounting Standards (Ind AS) under Section 133 of the Companies Act, 2013.

In compliance with Regulation 30 and 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company published the standalone unaudited financial results in "Free Express, Gujarat" (English) and "Lokmitra" (Gujarati) on July 16, 2026.